Applied Therapeutics Inc (APLT)

Currency in USD
0.476
+0.006(+1.28%)
Closed·
After Hours
0.4750.000(-0.02%)
·
APLT Scorecard
Full Analysis
Management has been aggressively buying back shares
Earnings results expected tomorrow
APLT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.4620.483
52 wk Range
0.29510.624
Key Statistics
Prev. Close
0.476
Open
0.47
Day's Range
0.462-0.483
52 wk Range
0.295-10.624
Volume
658.78K
Average Volume (3m)
2.15M
1-Year Change
-92.08%
Book Value / Share
0.32
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
APLT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
3.167
Upside
+565.27%
Members' Sentiments
Bearish
Bullish
ProTips
Holds more cash than debt on its balance sheet

Applied Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Applied Therapeutics Inc Company Profile

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company’s lead product candidate is AT-007 that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It develops AT-001 that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Applied Therapeutics Inc SWOT Analysis


Regulatory Progress
Explore Applied Therapeutics' positive FDA feedback on galactosemia treatment and potential accelerated approval for SORD therapy, signaling promising regulatory momentum
Market Expansion
Discover how revised SORD prevalence estimates have significantly increased Applied Therapeutics' addressable market, potentially boosting long-term revenue projections
Pipeline Potential
Delve into Applied Therapeutics' focus on galactosemia and SORD deficiency, positioning the company as a pioneer in addressing these rare genetic disorders
Financial Outlook
Analyst price targets range from $2 to $13, reflecting the speculative nature of Applied Therapeutics' development stage and the potential impact of regulatory decisions
Read full SWOT analysis

Compare APLT to Peers and Sector

Metrics to compare
APLT
Peers
Sector
Relationship
P/E Ratio
−1.5x−1.1x−0.5x
PEG Ratio
−0.02−0.060.00
Price/Book
1.8x2.3x2.6x
Price / LTM Sales
254.3x9.9x3.3x
Upside (Analyst Target)
-292.9%42.8%
Fair Value Upside
Unlock21.2%6.5%Unlock

Analyst Ratings

2 Buy
2 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 3.167
(+565.27% Upside)

Earnings

Latest Release
May 13, 2025
EPS / Forecast
-0.15 / -0.16
Revenue / Forecast
3.13M / 2.80M
EPS Revisions
Last 90 days

APLT Income Statement

People Also Watch

0.658
PSTV
-10.96%
44.750
RKLB
+0.47%
52.570
ASTS
+2.32%
0.043
NCNA
-6.56%

FAQ

What Stock Exchange Does Applied Therapeutics Trade On?

Applied Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Applied Therapeutics?

The stock symbol for Applied Therapeutics is "APLT."

What Is the Applied Therapeutics Market Cap?

As of today, Applied Therapeutics market cap is 67.32M.

What Is Applied Therapeutics's Earnings Per Share (TTM)?

The Applied Therapeutics EPS (TTM) is -0.30.

When Is the Next Applied Therapeutics Earnings Date?

Applied Therapeutics will release its next earnings report on 06 Aug 2025.

From a Technical Analysis Perspective, Is APLT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Applied Therapeutics Stock Split?

Applied Therapeutics has split 0 times.

How Many Employees Does Applied Therapeutics Have?

Applied Therapeutics has 36 employees.

What is the current trading status of Applied Therapeutics (APLT)?

As of 06 Aug 2025, Applied Therapeutics (APLT) is trading at a price of 0.48, with a previous close of 0.48. The stock has fluctuated within a day range of 0.46 to 0.48, while its 52-week range spans from 0.30 to 10.62.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.